Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

February 3, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

February 28, 2030

Conditions
Bronchopulmonary Dysplasia
Interventions
OTHER

Air-sham

Room air for intratracheal administration

DRUG

Zelpultide alfa

Reconstituted Zelpultide alfa for intratracheal administration

Trial Locations (18)

Unknown

Bnai Zion Medical Center, Haifa

Shaare-Zedek Medical Center, Jerusalem

Ziv Medical Center, Safed

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

"Ospedale dei Bambini V. Buzzi", Milan

Azienda Ospedale Università di Padova, Padua

Hospital General Universitario de Alicante Dr. Balmis, Alicante

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital Universitario Cruces - OSI Ezkerraldea-Enkarterri-Cruces, Bilbao

Hospital Universitario Puerta del Mar, Cadiz

Hospital Universitari Arnau de Vilanova de Lleida, Lleida

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario La Paz, Madrid

Hospital Regional Universitario de Málaga, Málaga

Hospital Clínico Universitario de Santiago, Santiago de Compostela

Hospital Universitari i Politècnic La Fe, Valencia

Hospital Universitario Miguel Servet, Zaragoza

Sponsors
All Listed Sponsors
lead

Airway Therapeutics, Inc.

INDUSTRY

NCT06897839 - Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) | Biotech Hunter | Biotech Hunter